Primcyv 125mg Capsule (Palbociclib)

Primcyv 125mg Capsule contains palbociclib, an oral targeted anticancer medicine that inhibits cyclin-dependent kinases 4 and 6 (CDK4/6). These enzymes help cells progress through the cell cycle. Blocking them can slow the growth of hormone-receptor-positive breast cancer cells. Palbociclib Capsule is used with endocrine therapy for selected patients with HR-positive, HER2-negative advanced or metastatic breast cancer.

The endocrine partner may be an aromatase inhibitor or fulvestrant depending on menopausal status, previous treatment and clinical setting. Primcyv 125mg Capsule is a prescription medicine and requires regular blood-count monitoring because neutropenia is common. The exact formulation matters: capsules and tablets can have different food instructions, so patients should follow the specific pack insert and oncologist’s directions.

For current Palbociclib 125mg Capsule availability in the present day, a licensed pharmacy or authorized oncology medication supplier in India could be consulted. Availability of the medication must be established before ordering, and its use must be on the recommendation of the oncologist alone.​

Palbociclib 125mg Capsule is used in combination with endocrine therapy for HR-positive, HER2-negative advanced or metastatic breast cancer. It may be combined with an aromatase inhibitor as initial endocrine-based therapy or with fulvestrant in patients whose disease has progressed after endocrine therapy, depending on the approved label and patient profile.

Pre menopausal or perimenopausal patients generally require ovarian suppression when appropriate. Palbociclib 125mg is not used as a stand-alone replacement for endocrine therapy in these settings. Treatment selection considers hormone-receptor and HER2 status, menopausal status, previous therapy, disease burden, organ function and potential drug interactions.

Palbociclib 125mg Capsule selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6). These kinases phosphorylate the retinoblastoma protein and help cells move from the G1 phase into the S phase of the cell cycle. In HR-positive, HER2-negative breast cancer, blocking CDK4/6 can slow cell-cycle progression and enhance the effect of endocrine therapy. Bone-marrow precursor cells are also sensitive to this pathway, which is why neutropenia is a frequent treatment-limiting toxicity.

Evidence context: The studies below are pivotal or widely cited evidence supporting the Palbociclib 125mg in major treatment settings. Trial results should not be interpreted as a guarantee of benefit for an individual patient, and exact eligibility must match the current approved indication and oncology guideline.

Primcyv 125mg Capsule may cause side effects, and their frequency varies by indication, dose, combination regimen and patient population. The list below highlights clinically important effects rather than assigning a single percentage across different trials.

The standard starting dose is 125 mg orally once daily for 21 consecutive days followed by 7 days off treatment, creating a 28-day cycle, in combination with appropriate endocrine therapy. Dose reductions for toxicity are commonly 100 mg once daily and then 75 mg once daily. Palbociclib 125mg Capsule is taken with food; tablet formulations have different food instructions, so the formulation on the pack matters. Premenopausal/perimenopausal women receiving an aromatase inhibitor or fulvestrant generally also receive an LHRH agonist.

Administration guidance: Take Primcyv 125mg Capsule exactly according to the prescribed 28-day cycle, commonly once daily for 21 consecutive days followed by 7 days without palbociclib. Because this product is a capsule, follow the capsule-specific instructions; palbociclib Capsules are generally taken with food. Swallow capsules whole and do not open, crush or chew them. Take the dose at approximately the same time each day. Blood counts are checked before and during treatment, particularly early cycles. The oncologist may delay palbociclib treatment, interrupt it or reduce the dose for neutropenia or other toxicity. Avoid grapefruit products and discuss all new medicines before starting them.

If a dose is missed or vomiting occurs after a dose, do not take an additional dose that day. Take the next dose at the regularly scheduled time.

CBC should be checked before treatment, at the start of each cycle, and around day 15 of the first two cycles, with additional monitoring as clinically indicated. Monitor for fever/infection and respiratory symptoms. Review hepatic impairment and CYP3A interactions.

1. FDA Ibrance (palbociclib) Prescribing Information.https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/207103s024lbl.pdf.​
2. EMA Ibrance Product Information / SmPC.https://www.ema.europa.eu/en/medicines/human/EPAR/ibrance​
3. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer.https://www.nccn.org/guidelines/guidelines-detail?id=1419.
4. National library of medicine. Palbociclib. https://pmc.ncbi.nlm.nih.gov/articles/PMC4128689/​